Showing 341 - 360 results of 367 for search '"Dexamethasone"', query time: 0.05s Refine Results
  1. 341

    HLA-DMB correlates with antitumor immunity and an improved prognosis in endometrial carcinoma tumors by Xiaoyu Xi, Xiaona Zhang, Jianxin Tang, Xiumei Fan, Jiexian Du

    Published 2025-01-01
    “…In our drug analysis, we identified several chemical agents associated with HLA-DMB, including cisplatin, dexamethasone, and ethinylestradiol.DiscussionThis study elucidates the function and underlying mechanisms of HLA-DMB in UCEC, providing a potential biomarker and target for immunotherapy in this disease.…”
    Get full text
    Article
  2. 342

    Synergistic anti-oxidative/anti-inflammatory treatment for acute lung injury with selenium based chlorogenic acid nanoparticles through modulating Mapk8ip1/MAPK and Itga2b/PI3k-AKT... by Huizhen Xing, Xinwei Bai, Xiaoying Pei, Yuqi Zhang, Xueying Zhang, Shujun Chen, Dan Li, Bin Lv, Xiaoying Wang, Xiaoli Wu

    Published 2025-01-01
    “…Additionally, with excellent biosafety, CHSe NPs exhibited superior therapeutic effects in ALI mice models in vivo, surpassing the performance of the clinic drug dexamethasone. They remarkably reduced ROS levels, and elevated the SOD and GPX enzyme activities in lung tissue to exert antioxidant effects. …”
    Get full text
    Article
  3. 343

    Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses by Chukwudi A. Ofodile, Ikemefuna C. Uzochukwu, Fortunatus C. Ezebuo, InnocentMary Ejiofor, Mercy Adebola, Innocent Okpoli, Beatrice Cubitt, Haydar Witwit, Chetachi B. Okwuanaso, Ngozi Onyemelukwe, Juan Carlos de la Torre

    Published 2025-01-01
    “…Our in silico docking screen identified five drugs (dexamethasone, tadalafil, mefloquine, ergocalciferol, and flunarizine) with strong predicted binding affinity to LASV proteins involved in the formation of the vRNP. …”
    Get full text
    Article
  4. 344

    Systemic antihyperalgesic effect of a novel conotoxin from Californiconus californicus in an inflammatory pain model by Joaquín López-Carrillo, Johanna Bernáldez-Sarabia, Tushar J. Pawar, Samanta Jiménez, Salvador Dueñas, Andrea Figueroa-Montiel, José L. Olivares-Romero, Vinicio Granados-Soto, Alexei F. Licea-Navarro, Alexei F. Licea-Navarro, Nadia L. Caram-Salas, Nadia L. Caram-Salas

    Published 2025-01-01
    “…Comparative analyses were conducted against O1_cal6.4d, ω-MVIIA, and standard analgesics (morphine, dexamethasone, and diclofenac). Structural differences between O1_cal6.4b and O1_cal6.4d were examined using in silico modeling and molecular dynamics simulations.ResultsSystemic administration of O1_cal6.4b significantly reduced thermal hyperalgesia in a dose-dependent manner without impairing motor coordination. …”
    Get full text
    Article
  5. 345

    Pharmacological evidence supporting a role for IL-1, IL-2 and serotonin in the inflammation induced by Schistosoma mansoni Soluble Egg Antigen (SEA) in rat paws by C. M. F. Pacheco, C. A. P. Tavares, P. M. Z. Coelho, O. A. Rocha, J. M. M. Santos, F. R. M. Prado, J. N. Francischi

    Published 1998-01-01
    “…Chronic tre atment with inhibitors of IL-2 synthesis / release such as cyclosporin or dexamethasone during the sens itization phase reduced the oedematogenic response due to SEA challenge by 51% and 55%, respectively. …”
    Get full text
    Article
  6. 346

    Oyster Mushroom (Pleurotus ostreatus) Ethanolic Extract Inhibits Pparg Expression While Maintaining the Methylation of the Pparg Promoter During 3T3-L1 Adipocyte Differentiation by Ariyanto EF, Farahana AK, Sudirman GSJ, Widiarsih E, Qomarilla N, Rahayu NS, Wikayani TP, Heryaman H, Wira DW, Triatin RD, Bashari MH, Pamela Y, Pratiwi YS, Ghozali M

    Published 2025-01-01
    “…Eko Fuji Ariyanto,1,2 Anastasya Kania Farahana,3 Gabriella Sachiko Jannesha Sudirman,3 Erlina Widiarsih,4 Nurul Qomarilla,5 Nurul Setia Rahayu,4 Tenny Putri Wikayani,5 Henhen Heryaman,1 Dwi Wahyudha Wira,1 Rima Destya Triatin,1,2 Muhammad Hasan Bashari,1 Yunisa Pamela,1 Yuni Susanti Pratiwi,1 Mohammad Ghozali1 1Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, West Java, Indonesia; 2Research Center for Medical Genetics, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia; 3Undergraduate Program of Medical Doctor, Faculty of Medicine, Universitas Padjadjaran, Sumedang, West Java, Indonesia; 4Molecular Genetics Laboratory, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia; 5Cell Culture Laboratory, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, IndonesiaCorrespondence: Eko Fuji Ariyanto, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Sumedang, West Java, Indonesia, Tel +6281316099791, Email fuji@unpad.ac.idPurpose: This study aims to provide new insights into the potential of oyster mushroom (Pleurotus ostreatus) ethanolic extract in preventing obesity through the inhibition of Pparg expression and modulation of methylation level on Pparg promoter during 3T3-L1 adipocyte differentiation.Methods: This in vitro quantitative experimental study was conducted by treating the 3T3-L1 cell line differentiated using 0.5 mM methyl-isobutyl-xanthine, 1 μM dexamethasone, and 10 μg/mL insulin-containing medium with oyster mushroom ethanolic extract. …”
    Get full text
    Article
  7. 347

    The role of natural exosomes from SHED-MSC in immunoregulation of M0/M1 polarized macrophage cells by Ali Fallah, Abasalt Hosseinzadeh Colagar, Ayyoob Khosravi, Ayyoob Khosravi, Azadeh Mohammad-Hasani, Azadeh Mohammad-Hasani, Mohsen Saeidi, Mohsen Saeidi

    Published 2025-02-01
    “…The immunoregulatory macromolecules were assessed by analyzing surface markers, cytokine production, and pro- and antioxidant activity.ResultsMacrophages treated with exosomes exhibited immunomodulatory effects akin to those treated with dexamethasone. The levels of anti-inflammatory and antioxidant markers, including CD206, Arg-1, IL-10, TGF-β, TAC, CAT, and SOD, which act as immunosuppressive macromolecules, were elevated. …”
    Get full text
    Article
  8. 348

    Lysozyme-based spray for treatment of radiotherapy-induced oral mucositis by Zdenka Gojković, Jelena Rožić, Nataša Gašpar, Aziz Šukalo, Meliha Mehić, Amna Tanović Avdić, Una Glamočlija

    Published 2025-01-01
    “…Patients were randomly divided into a lysozyme group (using a spray containing lysozyme + cetylpyridinium + lidocaine) and a control group (using a compounded preparation containing gentamicin + dexamethasone + lidocaine). The efficacy and safety of therapy were evaluated on the baseline and three follow-up visits (7, 14, and 21 days after the baseline visit). …”
    Get full text
    Article
  9. 349

    Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. by Westyn Branch-Elliman, Ryan Ferguson, Gheorghe Doros, Patricia Woods, Sarah Leatherman, Judith Strymish, Rupak Datta, Rekha Goswami, Matthew D Jankowich, Nishant R Shah, Thomas H Taylor, Sarah T Page, Sara J Schiller, Colleen Shannon, Cynthia Hau, Maura Flynn, Erika Holmberg, Karen Visnaw, Rupali Dhond, Mary Brophy, Paul A Monach

    Published 2022-01-01
    “…This occurred in 5/20 and 1/30 of participants in the sarilumab and SOC arms respectively, with the majority occurring in the initial 9 participants (3/4 in the sarilumab and 1/5 in the SOC) before the sarilumab dose was increased to 400 mg and before remdesivir and dexamethasone were widely adopted. After interim review, the unblinded Data Monitoring Committee recommended that the study be stopped due to concern for safety: a high probability that rates of intubation or death were higher with addition of sarilumab to SOC (92.6%), and a very low probability (3.4%) that sarilumab would be found to be superior.…”
    Get full text
    Article
  10. 350
  11. 351

    Knockdown of Gfi1 increases BMSCs exosomal miR-150-3p to inhibit osteoblast ferroptosis in steroid-induced osteonecrosis of the femoral head through BTRC/Nrf2 axis by Liwen Zheng, Changjie Zhang, Lele Liao, Zhijie Hai, Xin Luo, Haoliang Xiao

    Published 2025-02-01
    “…This study explored the role of exosomal miR-150-3p, derived from bone marrow mesenchymal stem cells (BMSCs), in osteoblast ferroptosis in SONFH. Dexamethasone (DEX) was used to treat osteoblasts to induce ferroptosis. …”
    Get full text
    Article
  12. 352

    The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study by Mostafa W. Galal, Mahmoud Ahmed, Yanqiu Shao, Chao Xing, Wael Ali, Abd Elhamid Baly, Abdallah Elfiky, Khaled Amer, John Schoggins, Hesham A. Sadek, Zeinab N. Gobara

    Published 2022-01-01
    “…Patients received standard-of-care treatment including remdesivir, dexamethasone, and anticoagulants as deemed necessary by the treating physician. …”
    Get full text
    Article
  13. 353

    Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study by Zhiqiang Zhao, Qinchuan Yu, Liping Su, Jianxia He, Jie Tao, Yanfeng Xi, Yujiao Guo, Yanhong Luo, Lieyang Wang

    Published 2025-01-01
    “…This retrospective observational study evaluates BV-based regimens in patients with sALCL, treated from 2020 to 2023.MethodsA multi-center observational retrospective study was conducted on patients with sALCL received BV plus cyclophosphamide, doxorubicin, and prednisone (CHP) upfront or BV plus gemcitabine, oxaliplatin(GemOx), gemcitabine, cisplatin, dexamethasone(GDP), or isocyclophosphamide, carboplatin, etoposide (ICE)for later lines. …”
    Get full text
    Article
  14. 354

    Changes of Lacrimal Puncta by Anterior Segment Optical Coherence Tomography after Topical Combined Antibiotic and Steroid Treatment in Cases of Inflammatory Punctual Stenosis by Islam Awny, Elshimaa A. Mateen Mossa, Tasneem Mohammed Bakheet, Hany Mahmoud, Amr Mounir

    Published 2022-01-01
    “…They were divided into two groups, the epiphora group one (EG1) received eye drops containing combination of antibiotics and steroids (orchadexoline eye drops, each ml contains 5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg hydroxypropyl methyl cellulose, 10 mg α-tocopherol acetate (vitamin E), and 8 mg macrogol 400), 5 times daily for the first week, three times daily for the next two weeks, and one time daily for another one week. …”
    Get full text
    Article
  15. 355

    New compounds with a dihydropyridine framework as promising hypolipidemic and hepatoprotective agents by Elena S. Ketova, Anna V. Myazina, Elena Yu. Bibik, Sergey G. Krivokolysko

    Published 2024-09-01
    “…To study the compounds in vivo, metabolic disorders were simulated in Wistar rats by long -term alimentary and subsequent dexamethasone loads. The pharmacological efficacy of new compounds AZ-383, AZ-257, AZ-020 (administered in a dose of 1 mg/kg for 14 days) was assessed in comparison with metformin (300 mg/kg for 14 days) and vildagliptin (8 mg/kg for 14 days) by determining the biochemical indicators of blood (ALT, AST, total bilirubin, total cholesterol, triglycerides, and glucose), morphological and morphometric studies of the liver sections, and the study of immunohistochemical indicators of hepatocyte proliferation. …”
    Get full text
    Article
  16. 356

    Extracellular matrix turnover in severe COVID-19 is reduced by corticosteroids by Janesh Pillay, Antine W. Flikweert, Matijs van Meurs, Marco J. Grootenboers, Simone van der Sar-van der Brugge, Peter H. J. van der Voort, Morten A. Karsdal, Jannie M. B. Sand, Diana J. Leeming, Janette K. Burgess, Jill Moser

    Published 2025-01-01
    “…Abstract Background Severe and critical COVID-19 is characterized by pulmonary viral infection with SARS-CoV-2 resulting in local and systemic inflammation. Dexamethasone (DEX) has been shown to improve outcomes in critically ill patients; however, its effect on tissue remodeling, particularly collagen turnover, remains unclear. …”
    Get full text
    Article
  17. 357

    Shengxue Busui Decoction activates the PI3K/Akt and VEGF pathways, enhancing vascular function and inhibiting osteocyte apoptosis to combat steroid-induced femoral head necrosis by Manting Liu, Jiexiang Ye, Runtian Wu, Dongqiang Luo, Tao Huang, Dandan Dai, Kexin Wang, Yanping Du, Junwen Ou

    Published 2025-01-01
    “…Cytoscape and machine learning (SVM) were used for target prediction and molecular docking validation. A dexamethasone (Dex)-induced SONFH rat model was established, and SBD was administered for 60 days. …”
    Get full text
    Article
  18. 358

    Anti-diabetic potential of apigenin, luteolin, and baicalein via partially activating PI3K/Akt/Glut-4 signaling pathways in insulin-resistant HepG2 cells by Lingchao Miao, Haolin Zhang, Meng Sam Cheong, Ruting Zhong, Paula Garcia-Oliveira, Miguel A. Prieto, Ka-Wing Cheng, Mingfu Wang, Hui Cao, Shaoping Nie, Jesus Simal-Gandara, Wai San Cheang, Jianbo Xiao

    Published 2023-11-01
    “…In this study, apigenin, luteolin, and baicalein were chosen to evaluate their anti-diabetic effect in high-glucose and dexamethasone induced insulin-resistant (IR) HepG2 cells. …”
    Get full text
    Article
  19. 359

    Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia by Marlise R. Luskin, Shai Shimony, Julia Keating, Eric S. Winer, Jacqueline S. Garcia, Richard M. Stone, Elias Jabbour, Yael Flamand, Kristen Stevenson, Jeremy Ryan, Zhihong Zeng, Anthony Letai, Marina Konopleva, Nitin Jain, Daniel J. DeAngelo

    Published 2025-02-01
    “…Venetoclax was given for 21 days with each cycle of mini–hyper-CVD (mini-HCVD; cyclophosphamide, vincristine, dexamethasone alternating with methotrexate and cytarabine). …”
    Get full text
    Article
  20. 360

    A Case of Undiagnosed HIV Infection in a 57-Year-Old Woman with Multiple Myeloma: Consequences on Chemotherapy Efficiency and Safety by I. Poizot-Martin, S. Brégigeon, C. Tamalet, R. Bouabdallah, O. Zaegel-Faucher, V. Obry-Roguet, A. Ivanova, C.E. Cano, C. Solas

    Published 2016-01-01
    “…A 57-year-old woman diagnosed with multiple myeloma underwent a first round of chemotherapy by bortezomib/lenalidomide and then with bortezomib/liposomal-doxorubicine/dexamethasone, with partial remission, poor hematological tolerance, and multiple episodes of pneumococcal infection. …”
    Get full text
    Article